157 results on '"Bont, Louis"'
Search Results
2. RSV Neutralizing Antibodies in Dried Blood.
- Author
-
Terstappen, Jonne, Delemarre, Eveline M, Versnel, Anouk, White, Joleen T, Derrien-Colemyn, Alexandrine, Ruckwardt, Tracy J, Bont, Louis J, and Mazur, Natalie I
- Subjects
CLINICAL trial registries ,RESPIRATORY syncytial virus ,VIRAL vaccines ,BLOOD sampling ,MONOCLONAL antibodies - Abstract
Background The key correlate of protection of respiratory syncytial virus (RSV) vaccines and monoclonal antibodies (mAbs) is virus neutralization, measured via sera obtained through venipuncture. Dried blood obtained with a finger prick can simplify acquisition, processing, storage, and transport in trials and thereby reduce costs. In this study, we validate an assay to measure RSV neutralization in dried capillary blood. Methods Functional antibodies were compared between matched serum and dried blood samples from a phase 1 trial with RSM01, an investigational anti-RSV prefusion F mAb. Hep-2 cells were infected with a serial dilution of sample-virus mixture by using RSV-A2-mKate to determine the half-maximal inhibitory concentration. Stability of dried blood was evaluated over time and during temperature stress. Results Functional antibodies in dried blood were highly correlated with serum (R
2 = 0.98, P <.0001). The precision of the assay for dried blood was similar to serum. The function of mAb remained stable for 9 months at room temperature and frozen dried blood samples. Conclusions We demonstrated the feasibility of measuring RSV neutralization using dried blood as a patient-centered solution that may replace serology testing in trials against RSV or other viruses, such as influenza and SARS-CoV-2. Clinical Trials Registration. NCT05118386 (ClinicalTrials.gov). [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
3. IgG1 glycosylation highlights premature aging in Down syndrome.
- Author
-
Streng, Bianca M. M., Van Coillie, Julie, Wildenbeest, Joanne G., Binnendijk, Rob S., Smits, Gaby, den Hartog, Gerco, Wang, Wenjun, Nouta, Jan, Linty, Federica, Visser, Remco, Wuhrer, Manfred, Vidarsson, Gestur, and Bont, Louis J.
- Subjects
PREMATURE aging (Medicine) ,LIQUID chromatography-mass spectrometry ,DOWN syndrome ,GLYCOSYLATION ,IMMUNE response ,FUCOSYLATION - Abstract
Down syndrome (DS) is characterized by lowered immune competence and premature aging. We previously showed decreased antibody response following SARS‐CoV‐2 vaccination in adults with DS. IgG1 Fc glycosylation patterns are known to affect the effector function of IgG and are associated with aging. Here, we compare total and anti‐spike (S) IgG1 glycosylation patterns following SARS‐CoV‐2 vaccination in DS and healthy controls (HC). Total and anti‐Spike IgG1 Fc N‐glycan glycoprofiles were measured in non‐exposed adults with DS and controls before and after SARS‐CoV‐2 vaccination by liquid chromatography–mass spectrometry (LC–MS) of Fc glycopeptides. We recruited N = 44 patients and N = 40 controls. We confirmed IgG glycosylation patterns associated with aging in HC and showed premature aging in DS. In DS, we found decreased galactosylation (50.2% vs. 59.0%) and sialylation (6.7% vs. 8.5%) as well as increased fucosylation (97.0% vs. 94.6%) of total IgG. Both cohorts showed similar bisecting GlcNAc of total and anti‐S IgG1 with age. In contrast, anti‐S IgG1 of DS and HC showed highly comparable glycosylation profiles 28 days post vaccination. The IgG1 glycoprofile in DS exhibits strong premature aging. The combination of an early decrease in IgG1 Fc galactosylation and sialylation and increase in fucosylation is predicted to reduce complement activity and decrease FcγRIII binding and subsequent activation, respectively. The altered glycosylation patterns, combined with decreased antibody concentrations, help us understand the susceptibility to severe infections in DS. The effect of premature aging highlights the need for individuals with DS to receive tailored vaccines and/or vaccination schedules. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Outpatient respiratory syncytial virus infections and novel preventive interventions.
- Author
-
Hak, Sarah F., Venekamp, Roderick P., Wildenbeest, Joanne G., and Bont, Louis J.
- Published
- 2024
- Full Text
- View/download PDF
5. Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus.
- Author
-
Lin, Gu-Lung, Drysdale, Simon B., Snape, Matthew D., O'Connor, Daniel, Brown, Anthony, MacIntyre-Cockett, George, Mellado-Gomez, Esther, de Cesare, Mariateresa, Ansari, M. Azim, Bonsall, David, Bray, James E., Jolley, Keith A., Bowden, Rory, Aerssens, Jeroen, Bont, Louis, Openshaw, Peter J. M., Martinon-Torres, Federico, Nair, Harish, Golubchik, Tanya, and Pollard, Andrew J.
- Subjects
RESPIRATORY syncytial virus ,RESPIRATORY syncytial virus infections ,INFANTS ,RESPIRATORY infections in children ,METAGENOMICS ,PATHOGENIC microorganisms - Abstract
Respiratory syncytial virus (RSV) is the leading cause of hospitalisation for respiratory infection in young children. RSV disease severity is known to be age-dependent and highest in young infants, but other correlates of severity, particularly the presence of additional respiratory pathogens, are less well understood. In this study, nasopharyngeal swabs were collected from two cohorts of RSV-positive infants <12 months in Spain, the UK, and the Netherlands during 2017–20. We show, using targeted metagenomic sequencing of >100 pathogens, including all common respiratory viruses and bacteria, from samples collected from 433 infants, that burden of additional viruses is common (111/433, 26%) but only modestly correlates with RSV disease severity. In contrast, there is strong evidence in both cohorts and across age groups that presence of Haemophilus bacteria (194/433, 45%) is associated with higher severity, including much higher rates of hospitalisation (odds ratio 4.25, 95% CI 2.03–9.31). There is no evidence for association between higher severity and other detected bacteria, and no difference in severity between RSV genotypes. Our findings reveal the genomic diversity of additional pathogens during RSV infection in infants, and provide an evidence base for future causal investigations of the impact of co-infection on RSV disease severity. The impact of other pathogens on disease outcome was studied in European infants with RSV infection. Additional viruses were commonly co-detected during infection but were weakly linked to severity. However, presence of Haemophilus bacteria strongly associated with severe cases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants.
- Author
-
Johnson, Mari, Chelysheva, Irina, Öner, Deniz, McGinley, Joseph, Lin, Gu-Lung, O'Connor, Daniel, Robinson, Hannah, Drysdale, Simon B, Gammin, Emma, Vernon, Sophie, Muller, Jill, Wolfenden, Helen, Westcar, Sharon, Anguvaa, Lazarus, Thwaites, Ryan S, Bont, Louis, Wildenbeest, Joanne, Martinón-Torres, Federico, Aerssens, Jeroen, and Openshaw, Peter J M
- Subjects
RESPIRATORY syncytial virus infections ,GENOME-wide association studies ,GENE expression ,INFANTS ,FALSE discovery rate - Abstract
Background Respiratory syncytial virus (RSV) is a significant cause of infant morbidity and mortality worldwide. Most children experience at least one 1 RSV infection by the age of two 2 years, but not all develop severe disease. However, the understanding of genetic risk factors for severe RSV is incomplete. Consequently, we conducted a genome-wide association study of RSV severity. Methods Disease severity was assessed by the ReSVinet scale, in a cohort of 251 infants aged 1 week to 1 year. Genotyping data were collected from multiple European study sites as part of the RESCEU Consortium. Linear regression models were used to assess the impact of genotype on RSV severity and gene expression as measured by microarray. Results While no SNPs reached the genome-wide statistical significance threshold (P < 5 × 10
−8 ), we identified 816 candidate SNPs with a P -value of <1 × 10−4 . Functional annotation of candidate SNPs highlighted genes relevant to neutrophil trafficking and cytoskeletal functions, including LSP1 and RAB27A. Moreover, SNPs within the RAB27A locus significantly altered gene expression (false discovery rate, FDR P <.05). Conclusions These findings may provide insights into genetic mechanisms driving severe RSV infection, offering biologically relevant information for future investigations. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
7. RESCEU and PROMISE: The Success of 8 Years of European Public-Private Partnership to Prevent RSV.
- Author
-
Vernhes, Charlotte, Bont, Louis, Demont, Clarisse, and Nair, Harish
- Subjects
PUBLIC-private sector cooperation ,RESPIRATORY syncytial virus infections ,RESPIRATORY infections ,ARTIFICIAL respiration - Abstract
The article discusses the success of the RESCEU and PROMISE initiatives, which are European public-private partnerships aimed at preventing respiratory syncytial virus (RSV). The RESCEU initiative, launched in 2017, focused on deepening understanding of RSV through collaboration between researchers and scientists from the public and private sectors. Despite the challenges posed by the COVID-19 pandemic, the initiative produced high-quality research that informed policy on RSV surveillance and recommendations for RSV vaccines and monoclonal antibodies. The PROMISE initiative, funded in 2021, aims to build on the achievements of RESCEU and address remaining key questions about RSV. The article highlights the need for continued collaboration in infectious disease prevention and control to develop life-saving interventions and ensure equitable access. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
8. Substantial Burden of Nonmedically Attended RSV Infection in Healthy-Term Infants: An International Prospective Birth Cohort Study.
- Author
-
Hak, Sarah F, Venekamp, Roderick P, Billard, Marie-Noëlle, Houten, Marlies A van, Pollard, Andrew J, Heikkinen, Terho, Cunningham, Steve, Millar, Margaret, Martinón-Torres, Federico, Dacosta-Urbieta, Ana, Bont, Louis J, Wildenbeest, Joanne G, and Investigators, PROMISE
- Subjects
RESPIRATORY syncytial virus infections ,COHORT analysis ,RESPIRATORY syncytial virus ,INFANTS ,CLINICAL trial registries - Abstract
Background During the first year of life, 1 in 4 infants develops a symptomatic respiratory syncytial virus (RSV) infection, yet only half seek medical attention. The current focus on medically attended RSV therefore underrepresents the true societal burden of RSV. We assessed the burden of nonmedically attended RSV infections and compared with medically attended RSV. Methods We performed active RSV surveillance until the age of 1 year in a cohort (n = 993) nested within the Respiratory Syncytial Virus Consortium in EUrope (RESCEU) prospective birth cohort study enrolling healthy term-born infants in 5 European countries. Symptoms, medication use, wheezing, and impact on family life were analyzed. Results For 97 of 120 (80.1%) nonmedically attended RSV episodes, sufficient data were available for analysis. In 50.5% (49/97), symptoms lasted ≥15 days. Parents reported impairment in usual daily activities in 59.8% (58/97) of episodes; worries, 75.3% (73/97); anxiety, 34.0% (33/97); and work absenteeism, 10.8% (10/93). Compared with medically attended RSV (n = 102, 9 hospital admissions), Respiratory Syncytial Virus NETwork (ReSViNET) severity scores were lower (3.5 vs 4.6, P <.001), whereas duration of respiratory symptoms and was comparable. Conclusions Even when medical attendance is not required, RSV infection poses a substantial burden to infants, families, and society. These findings are important for policy makers when considering the implementation of RSV immunization. Clinical Trials Registration. ClinicalTrials.gov (NCT03627572). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Validity of Clinical Severity Scores for Respiratory Syncytial Virus: A Systematic Review.
- Author
-
Sheikh, Zakariya, Potter, Ellie, Li, You, Cohen, Rachel A, Santos, Gaël Dos, Bont, Louis, Nair, Harish, and Investigators, PROMISE
- Subjects
BRONCHIOLITIS ,RESPIRATORY syncytial virus ,RESPIRATORY infections ,RESPIRATORY syncytial virus infections ,PREDICTION models - Abstract
Background Respiratory syncytial virus (RSV) is a widespread respiratory pathogen, and RSV-related acute lower respiratory tract infections are the most common cause of respiratory hospitalization in children <2 years of age. Over the last 2 decades, a number of severity scores have been proposed to quantify disease severity for RSV in children, yet there remains no overall consensus on the most clinically useful score. Methods We conducted a systematic review of English-language publications in peer-reviewed journals published since January 2000 assessing the validity of severity scores for children (≤24 months of age) with RSV and/or bronchiolitis, and identified the most promising scores. For included articles, (1) validity data were extracted, (2) quality of reporting was assessed using the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis checklist (TRIPOD), and (3) quality was assessed using the Prediction Model Risk Of Bias Assessment Tool (PROBAST). To guide the assessment of the validity data, standardized cutoffs were employed, and an explicit definition of what we required to determine a score was sufficiently validated. Results Our searches identified 8541 results, of which 1779 were excluded as duplicates. After title and abstract screening, 6670 references were excluded. Following full-text screening and snowballing, 32 articles, including 31 scores, were included. The most frequently assessed scores were the modified Tal score and the Wang Bronchiolitis Severity Score; none of the scores were found to be sufficiently validated according to our definition. The reporting and/or design of all the included studies was poor. The best validated score was the Bronchiolitis Score of Sant Joan de Déu, and a number of other promising scores were identified. Conclusions No scores were found to be sufficiently validated. Further work is warranted to validate the existing scores, ideally in much larger datasets. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. External Validation of the Discriminative Validity of the ReSVinet Score and Development of Simplified ReSVinet Scores in Secondary Care.
- Author
-
Sheikh, Zakariya, Potter, Ellie, Li, You, Drysdale, Simon B, Wildenbeest, Joanne G, Robinson, Hannah, McGinley, Joseph, Lin, Gu-Lung, Öner, Deniz, Aerssens, Jeroen, Justicia-Grande, Antonio José, Martinón-Torres, Federico, Pollard, Andrew J, Bont, Louis, and Nair, Harish
- Subjects
BRONCHIOLITIS ,SECONDARY care (Medicine) ,RECEIVER operating characteristic curves ,RESOURCE-limited settings ,RESPIRATORY syncytial virus ,INTENSIVE care units ,VACCINES - Abstract
Background There is no consensus on how to best quantify disease severity in infants with respiratory syncytial virus (RSV) and/or bronchiolitis; this lack of a sufficiently validated score complicates the provision of clinical care and, the evaluation of trials of therapeutics and vaccines. The ReSVinet score appears to be one of the most promising; however, it is too time consuming to be incorporated into routine clinical care. We aimed to develop and externally validate simplified versions of this score. Methods Data from a multinational (the Netherlands, Spain, and United Kingdom) multicenter case-control study of infants with RSV were used to develop simplified versions of the ReSVinet score by conducting a grid search to determine the best combination of equally weighted parameters to maximize for the discriminative ability (measured by area under the receiver operating characteristic curve [AUROC]) across a range of outcomes (hospitalization, intensive care unit admission, ventilation requirement). Subsequently discriminative validity of the score for a range of secondary care outcomes was externally validated by secondary analysis of datasets from Rwanda and Colombia. Results Three candidate simplified scores were identified using the development dataset; they were excellent (AUROC >0.9) at discriminating for a range of outcomes, and their performance was not significantly different from the original ReSVinet score despite having fewer parameters. In the external validation datasets, the simplified scores were moderate to excellent (AUROC, 0.7–1) across a range of outcomes. In all outcomes, except in a single dataset for predicting admission to the high-dependency unit, they performed at least as well as the original ReSVinet score. Conclusions The candidate simplified scores developed require further external validation in larger datasets, ideally from resource-limited settings before any recommendation regarding their use. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Personalized Infant Risk Prediction for Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection Requiring Intensive Care Unit Admission.
- Author
-
Snyder, Brittney M, Achten, Niek B, Gebretsadik, Tebeb, Wu, Pingsheng, Mitchel, Edward F, Escobar, Gabriel, Bont, Louis J, and Hartert, Tina V
- Abstract
Background Currently, there are no available tools to identify infants at the highest risk of significant morbidity and mortality from respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) who would benefit most from RSV prevention products. The objective was to develop and internally validate a personalized risk prediction tool for use among all newborns that uses readily available birth/postnatal data to predict RSV LRTI requiring intensive care unit (ICU) admission. Methods We conducted a population-based birth cohort study of infants born from 1995 to 2007, insured by the Tennessee Medicaid Program, and who did not receive RSV immunoprophylaxis during the first year of life. The primary outcome was severe RSV LRTI requiring ICU admission during the first year of life. We built a multivariable logistic regression model including demographic and clinical variables available at or shortly after birth to predict the primary outcome. Results In a population-based sample of 429 365 infants, 713 (0.2%) had severe RSV LRTI requiring ICU admission. The median age of admission was 66 days (interquartile range, 37–120). Our tool, including 19 variables, demonstrated good predictive accuracy (area under the curve, 0.78; 95% confidence interval, 0.77-0.80) and identified infants who did not qualify for palivizumab, based on American Academy of Pediatrics guidelines, but had higher predicted risk levels than infants who qualified (27% of noneligible infants with >0.16% predicted probabilities [lower quartile for eligible infants]). Conclusions We developed a personalized tool that identified infants at increased risk for severe RSV LRTI requiring ICU admission, expected to benefit most from immunoprophylaxis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Maternal diet and human milk composition: an updated systematic review.
- Author
-
Petersohn, Inga, Hellinga, Anneke H., van Lee, Linde, Keukens, Nicole, Bont, Louis, Hettinga, Kasper A., Feskens, Edith J. M., and Brouwer-Brolsma, Elske M.
- Published
- 2024
- Full Text
- View/download PDF
13. Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study.
- Author
-
van Boven, Michiel, van Dorp, Christiaan H., Westerhof, Ilse, Jaddoe, Vincent, Heuvelman, Valerie, Duijts, Liesbeth, Fourie, Elandri, Sluiter-Post, Judith, van Houten, Marlies A., Badoux, Paul, Euser, Sjoerd, Herpers, Bjorn, Eggink, Dirk, de Hoog, Marieke, Boom, Trisja, Wildenbeest, Joanne, Bont, Louis, Rozhnova, Ganna, Bonten, Marc J., and Kretzschmar, Mirjam E.
- Subjects
SARS-CoV-2 ,LONGITUDINAL method ,INFECTIOUS disease transmission ,HOSPITAL admission & discharge ,STOCHASTIC models - Abstract
Household studies provide an efficient means to study transmission of infectious diseases, enabling estimation of susceptibility and infectivity by person-type. A main inclusion criterion in such studies is usually the presence of an infected person. This precludes estimation of the hazards of pathogen introduction into the household. Here we estimate age- and time-dependent household introduction hazards together with within household transmission rates using data from a prospective household-based study in the Netherlands. A total of 307 households containing 1, 209 persons were included from August 2020 until March 2021. Follow-up of households took place between August 2020 and August 2021 with maximal follow-up per household mostly limited to 161 days. Almost 1 out of 5 households (59/307) had evidence of an introduction of SARS-CoV-2. We estimate introduction hazards and within-household transmission rates in our study population with penalized splines and stochastic epidemic models, respectively. The estimated hazard of introduction of SARS-CoV-2 in the households was lower for children (0-12 years) than for adults (relative hazard: 0.62; 95%CrI: 0.34-1.0). Estimated introduction hazards peaked in mid October 2020, mid December 2020, and mid April 2021, preceding peaks in hospital admissions by 1-2 weeks. Best fitting transmission models included increased infectivity of children relative to adults and adolescents, such that the estimated child-to-child transmission probability (0.62; 95%CrI: 0.40-0.81) was considerably higher than the adult-to-adult transmission probability (0.12; 95%CrI: 0.057-0.19). Scenario analyses indicate that vaccination of adults can strongly reduce household infection attack rates and that adding adolescent vaccination offers limited added benefit. Author summary: Households are a main setting for transmission of respiratory viruses. Here, we analyse data from a prospective household study to estimate the time-dependent hazards of introduction of SARS-CoV-2 into Dutch households as well as the person-to-person transmission rates within households. The analyses show that introduction hazards vary strongly over time, consistently preceding peaks in hospital admissions by 1-2 weeks. Estimated child-to-child transmission rates are much higher than estimates for other transmission routes. Using the best-fitting model, we simulate household outbreaks with vaccination of adults, or with vaccination of both adults and adolescents. Our analyses suggest limited benefit of adding adolescent vaccination to an adult vaccination campaign. We discuss the implications of these results for the household dynamics and control of SARS-CoV-2. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Incorporating Data from Multiple Endpoints in the Analysis of Clinical Trials: Example from RSV Vaccines.
- Author
-
Prunas, Ottavia, Willemsen, Joukje E., Bont, Louis, Pitzer, Virginia E., Warren, Joshua L., and Weinberger, Daniel M.
- Published
- 2024
- Full Text
- View/download PDF
15. Single‐cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants.
- Author
-
Zivanovic, Nevena, Öner, Deniz, Abraham, Yann, McGinley, Joseph, Drysdale, Simon B., Wildenbeest, Joanne G., Crabbe, Marjolein, Vanhoof, Greet, Thys, Kim, Thwaites, Ryan S., Robinson, Hannah, Bont, Louis, Openshaw, Peter J. M., Martinón‐Torres, Federico, Pollard, Andrew J., and Aerssens, Jeroen
- Subjects
RESPIRATORY syncytial virus infections ,INFANT diseases ,RESPIRATORY syncytial virus ,B cells - Abstract
Whereas most infants infected with respiratory syncytial virus (RSV) show no or only mild symptoms, an estimated 3 million children under five are hospitalized annually due to RSV disease. This study aimed to investigate biological mechanisms and associated biomarkers underlying RSV disease heterogeneity in young infants, enabling the potential to objectively categorize RSV‐infected infants according to their medical needs. Immunophenotypic and functional profiling demonstrated the emergence of immature and progenitor‐like neutrophils, proliferative monocytes (HLA‐DRLow, Ki67+), impaired antigen‐presenting function, downregulation of T cell response and low abundance of HLA‐DRLow B cells in severe RSV disease. HLA‐DRLow monocytes were found as a hallmark of RSV‐infected infants requiring hospitalization. Complementary transcriptomics identified genes associated with disease severity and pointed to the emergency myelopoiesis response. These results shed new light on mechanisms underlying the pathogenesis and development of severe RSV disease and identified potential new candidate biomarkers for patient stratification. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Year-Round Respiratory Syncytial Virus Transmission in The Netherlands Following the COVID-19 Pandemic: A Prospective Nationwide Observational and Modeling Study.
- Author
-
Löwensteyn, Yvette N, Zheng, Zhe, Rave, Neele, Bannier, Michiel A G E, Billard, Marie-Noëlle, Casalegno, Jean-Sebastien, Pitzer, Virginia E, Wildenbeest, Joanne G, Weinberger, Daniel M, Bont, Louis, and Group, for the Surveillance of Pediatric REspiratory Admissions in Dutch hospitals (SPREAD) Study
- Subjects
RESPIRATORY syncytial virus ,COVID-19 pandemic ,SCIENTIFIC observation ,DYNAMIC simulation ,VENTILATION monitoring - Abstract
We initiated a nationwide prospective study to monitor respiratory syncytial virus (RSV)–related pediatric hospitalizations in 46 hospitals throughout the Netherlands between May 2021 and August 2022. We showed year-round RSV transmission in the Netherlands after an initial 2021 summer outbreak. The pattern was unprecedented and distinct from neighboring countries. We extended a dynamic simulation model to evaluate the impact of waning immunity on pediatric RSV hospitalizations in the Netherlands using 4 different scenarios. Our results suggest that the observed continuous RSV transmission pattern could be associated with waning immunity due to the period of very low RSV circulation during the COVID-19 pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. T cells, more than antibodies, may prevent symptoms developing from respiratory syncytial virus infections in older adults.
- Author
-
Salaun, Bruno, De Smedt, Jonathan, Vernhes, Charlotte, Moureau, Annick, Öner, Deniz, Bastian, Arangassery Rosemary, Janssens, Michel, Balla-Jhagjhoorsingh, Sunita, Aerssens, Jeroen, Lambert, Christophe, Coenen, Samuel, Butler, Christopher C., Drysdale, Simon B., Wildenbeest, Joanne G., Pollard, Andrew J., Openshaw, Peter J. M., and Bont, Louis
- Subjects
RESPIRATORY syncytial virus infections ,OLDER people ,T cells ,RESPIRATORY infections ,RECEIVER operating characteristic curves - Abstract
Introduction: The immune mechanisms supporting partial protection from reinfection and disease by the respiratory syncytial virus (RSV) have not been fully characterized. In older adults, symptoms are typically mild but can be serious in patients with comorbidities when the infection extends to the lower respiratory tract. Methods: This study formed part of the RESCEU older-adults prospective-cohort study in Northern Europe (2017–2019; NCT03621930) in which a thousand participants were followed over an RSV season. Peripheral-blood samples (taken pre-season, post-season, during illness and convalescence) were analyzed from participants who (i) had a symptomatic acute respiratory tract infection by RSV (RSV-ARTI; N=35) or (ii) asymptomatic RSV infection (RSV-Asymptomatic; N=16). These analyses included evaluations of antibody (Fc-mediated–) functional features and cell-mediated immunity, in which univariate and machine-learning (ML) models were used to explore differences between groups. Results: Pre–RSV-season peripheral-blood biomarkers were predictive of symptomatic RSV infection. T-cell data were more predictive than functional antibody data (area under receiver operating characteristic curve [AUROC] for the models were 99% and 76%, respectively). The pre-RSV season T-cell phenotypes which were selected by the ML modelling and which were more frequent in RSV-Asymptomatic group than in the RSV-ARTI group, coincided with prominent phenotypes identified during convalescence from RSV-ARTI (e.g., IFN-γ+, TNF-α+ and CD40L+ for CD4+, and IFN-γ+ and 4-1BB+ for CD8+). Conclusion: The evaluation and statistical modelling of numerous immunological parameters over the RSV season suggests a primary role of cellular immunity in preventing symptomatic RSV infections in older adults. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Bacterial Colonization of the Lower Airways in Children With Esophageal Atresia.
- Author
-
van Tuyll van Serooskerken, Eleonora Sofie, Duhoky, Rauand, Verweij, Johannes W., Bont, Louis, Arets, Hubertus G. M., Bittermann, Arnold J. N., van der Zee, David C., Tytgat, Stefaan H. A. J., and Lindeboom, Maud Y. A.
- Published
- 2023
- Full Text
- View/download PDF
19. Lethal Respiratory Syncytial Virus in Zambia Is Sensitive to Longacting Monoclonal Antibodies.
- Author
-
Langedijk, Annefleur C., Vrancken, Bram, Lebbink, Robert Jan, Evers, Anouk, Pieciak, Rachel C., Lemey, Philippe, Bont, Louis J., and Gill, Christopher J.
- Published
- 2023
- Full Text
- View/download PDF
20. Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data.
- Author
-
Rozenbaum, Mark H., Begier, Elizabeth, Kurosky, Samantha K., Whelan, Jo, Bem, Danai, Pouwels, Koen B., Postma, Maarten, and Bont, Louis
- Subjects
RESPIRATORY syncytial virus infections ,OLDER people ,HUMAN metapneumovirus infection ,SEASONAL variations of diseases ,RESPIRATORY syncytial virus ,LITERATURE reviews ,POLYMERASE chain reaction - Abstract
Introduction: Respiratory syncytial virus (RSV) is an important cause of severe respiratory illness in older adults and adults with respiratory or cardiovascular comorbidities. Published estimates of its incidence and prevalence in adult groups vary widely. This article reviews the potential limitations affecting RSV epidemiology studies and suggests points to consider when evaluating or designing them. Methods: Studies reporting the incidence or prevalence of RSV infection in adults in high-income Western countries from 2000 onwards were identified via a rapid literature review. Author-reported limitations were recorded, together with presence of other potential limitations. Data were synthesized narratively, with a focus on factors affecting incidence estimates for symptomatic infection in older adults. Results: A total of 71 studies met the inclusion criteria, most in populations with medically attended acute respiratory illness (ARI). Only a minority used case definitions and sampling periods tailored specifically to RSV; many used influenza-based or other criteria that are likely to result in RSV cases being missed. The great majority relied solely on polymerase chain reaction (PCR) testing of upper respiratory tract samples, which is likely to miss RSV cases compared with dual site sampling and/or addition of serology. Other common limitations were studying a single season, which has potential for bias due to seasonal variability; failure to stratify results by age, which underestimates the burden of severe disease in older adults; limited generalizability beyond a limited study setting; and absence of measures of uncertainty in the reporting of results. Conclusions: A significant proportion of studies are likely to underestimate the incidence of RSV infection in older adults, although the effect size is unclear and there is also potential for overestimation. Well-designed studies, together with increased testing for RSV in patients with ARI in clinical practice, are required to accurately capture both the burden of RSV and the potential public health impact of vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Immune Response following BNT162b2 mRNA COVID-19 Vaccination in Pediatric Cancer Patients.
- Author
-
Schmidt, K. L. Juliëtte, Dautzenberg, Noël M. M., Hoogerbrugge, Peter M., Lindemans, Caroline A., Nierkens, Stefan, Smits, Gaby, Van Binnendijk, Rob S., Bont, Louis J., and Tissing, Wim J. E.
- Subjects
COVID-19 ,IMMUNIZATION ,COVID-19 vaccines ,VACCINE immunogenicity ,PEDIATRICS ,TUMORS in children ,VACCINE effectiveness ,CANCER patients ,ANTIBODY formation ,COMPARATIVE studies ,MESSENGER RNA ,DESCRIPTIVE statistics ,IMMUNOTHERAPY - Abstract
Simple Summary: Children with cancer experience a more severe SARS-CoV-2 infection and more often die due to COVID-19 than their healthy peers. Vaccination against SARS-CoV-2 is therefore recommend in children with cancer but little is known about their immune response following vaccination. With this study we aimed to investigate the effect of a 2- and/or 3-dose vaccination series in children who are undergoing active cancer treatment and in children that finished their cancer treatment. The results from this study show that compared to 2-dose vaccination, a 3-dose vaccination series was more effective in boosting antibody levels and is therefore of value for children undergoing active cancer treatment. The findings from this study provide evidence for the significance of COVID-19 vaccination in children undergoing cancer treatment and are also important for future vaccination strategies in children with cancer. COVID-19 vaccinations are recommended for children with cancer but data on their vaccination response is scarce. This study assesses the antibody and T-cell response following a 2- or 3-dose vaccination with BNT162b2 mRNA COVID-19 vaccine in children (5–17 years) with cancer. For the antibody response, participants with a serum concentration of anti-SARS-CoV-2 spike 1 antibodies of >300 binding antibody units per milliliter were classified as good responders. For the T-cell response, categorization was based on spike S1 specific interferon-gamma release with good responders having >200 milli-international units per milliliter. The patients were categorized as being treated with chemo/immunotherapy for less than 6 weeks (Tx < 6 weeks) or more than 6 weeks (Tx > 6 weeks) before the first immunization event. In 46 patients given a 2-dose vaccination series, the percentage of good antibody and good T-cell responders was 39.3% and 73.7% in patients with Tx < 6 weeks and 94.4% and 100% in patients with Tx > 6 weeks, respectively. An additional 3rd vaccination in 16 patients with Tx < 6 weeks, increased the percentage of good antibody responders to 70% with no change in T-cell response. A 3-dose vaccination series effectively boosted antibody levels and is of value for patients undergoing active cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Epidemiology of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Tract Infection among Hospitalized Under-5s in Northwestern Nigeria.
- Author
-
Garba, Maria Ahuoiza, Giwa, Fatima Jummai, Adelaiye, Hamdala, Olorukooba, Abiola Aira, Abdullahi, Fatima, Makarfi, Hauwa, Löwensteyn, Yvette, Bont, Louis, Abdurraheem, Fadlullah, Uudu, Ehi, Mudasir, Halima, and Mazur, Natalie I
- Subjects
RESPIRATORY infections ,PNEUMONIA-related mortality ,RESPIRATORY syncytial virus ,RESPIRATORY syncytial virus infection vaccines ,VACCINATION status - Abstract
Objective Globally, 33 million cases of respiratory syncytial virus (RSV) infections occur annually among under-fives (5s). Ninety-nine percent of deaths from RSV occur in low- and middle-income countries. Under-five pneumonia mortality in Nigeria was estimated at 140,520 in 2017, but RSV epidemiological data are scant due to poor awareness and limited testing. Vaccines for RSV are currently under development and RSV mortality data from this high mortality, low resource setting are essential to maximizing the potential benefit of vaccination as well as promoting vaccine uptake. This study aimed to describe the epidemiology of RSV-associated acute lower respiratory tract infection (ALRTI) in children younger than 5 years in Zaria, Northwestern Nigeria. Methods A prospective cohort study was conducted among children aged 1 month to 5 years who were hospitalized with ALRTI in the Emergency Pediatric Unit of a tertiary hospital in Zaria from November 2018 to October 2019. Naso-pharyngeal swabs were obtained for RSV testing using a point-of-care immunoassay technique. Results Thirty-three percent (35/106) of the children had RSV-related ALRTI. The median age of RSV-positive cases was 8 months (IQR 3–14). Two-thirds of children (68.6%, 24/35) were below 12 months. The RSV mortality rate was 5.7% (2/35). RSV occurred in 10 months of the year with peaks in March and July. Conclusion A third of admitted children with ALRTI were positive for RSV. Therefore RSV significantly contributes to childhood pneumonia and the dual seasonal peak observed in our study may have implications for vaccine implementation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Nosocomial RSV-related In-hospital Mortality in Children <5 Years: A Global Case Series.
- Author
-
Löwensteyn, Yvette N., Willemsen, Joukje E., Mazur, Natalie I., Scheltema, Nienke M., van Haastregt, Nynke C. J., Buuren, Amber A. A. ten, van Roessel, Ichelle, Scheepmaker, Dunja, Nair, Harish, van de Ven, Peter M., and Bont, Louis J.
- Published
- 2023
- Full Text
- View/download PDF
24. Differential isoform expression of Allergin‐1 during acute and chronic inflammation.
- Author
-
Geerdink, Ruben J., Pascoal Ramos, Maria Inês, van den Hoogen, Luuk L., Radstake, Timothy R. D. J., Shibayama, Shiro, Shibuya, Akira, Bont, Louis, and Meyaard, Linde
- Subjects
MYELOID cells ,SYSTEMIC lupus erythematosus ,RESPIRATORY syncytial virus ,B cells ,BASOPHILS - Abstract
Introduction: Neutrophils are crucial to antimicrobial defense, but excessive neutrophilic inflammation elicits immune pathology. Currently, no effective treatment exists to curb neutrophil activation. However, neutrophils express a variety of inhibitory receptors which may represent potential therapeutic targets to limit neutrophilic inflammation. Indeed, we previously showed that the inhibitory collagen receptor leukocyte‐associated immunoglobulin‐like receptor 1 (LAIR‐1) regulates neutrophilic airway inflammation and inhibits neutrophil extracellular trap formation. The inhibitory receptor Allergin‐1 is expressed by myeloid cells and B cells. Allergin‐1 suppresses mast cell and basophil activation, but a potential regulatory role on neutrophils remains unexplored. We aimed to demonstrate the regulation of neutrophils by Allergin‐1. Methods: We examine Allergin‐1 isoform expression on human neutrophils during homeostatic (healthy donors) and chronic inflammatory (systemic lupus erythematosus patients) conditions in comparison to other circulating leukocytes by flow cytometry. To reveal a potential role for Allergin‐1 in regulating neutrophilic inflammation, we experimentally infect wild‐type (WT) and Allergin‐1‐deficient mice with a respiratory syncytial virus (RSV) and monitor disease severity and examine cellular airway infiltrate. Flow cytometry was used to confirm Allergin‐1 expression by airway‐infiltrated neutrophils in RSV infection‐induced bronchiolitis patients. Results: Only the short 1 (S1) isoform, but not the long (L) or S2 isoform could be detected on blood leukocytes, with the exception of nonclassical monocytes, which exclusively express the S2 isoform. Allergin‐1 expression levels did not vary significantly between healthy individuals and patients with the systemic inflammatory disease on any interrogated cell type. Airway‐infiltrated neutrophils of pediatric RSV bronchiolitis patients were found to express Allergin‐1S1. However, Allergin‐1‐deficient mice experimentally infected with RSV did not show exacerbated disease or increased neutrophil airway infiltration compared to WT littermates. Conclusion: Allergin‐1 isoform expression is unaffected by chronic inflammatory conditions. In stark contrast to fellow inhibitory receptor LAIR‐1, Allergin‐1 does not regulate neutrophilic inflammation in a mouse model of RSV bronchiolitis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Patients with Chromosome 11q Deletions Are Characterized by Inborn Errors of Immunity Involving both B and T Lymphocytes.
- Author
-
Huisman, Elise J., Brooimans, A. Rick, Mayer, Samone, Joosten, Marieke, de Bont, Louis, Dekker, Mariëlle, Rammeloo, Elisabeth L. M., Smiers, Frans J., van Hagen, P. Martin, Zwaan, C. Michel, de Haas, Masja, Cnossen, Marjon H., and Dalm, Virgil A. S. H.
- Subjects
T cells ,B cells ,WARTS ,EAR infections ,RESPIRATORY infections ,CHROMOSOMES ,LYMPHOCYTE count - Abstract
Disorders of the long arm of chromosome 11 (11q) are rare and involve various chromosomal regions. Patients with 11q disorders, including Jacobsen syndrome, often present with a susceptibility for bacterial and prolonged viral and fungal infections partially explained by hypogammaglobulinemia. Additional T lymphocyte or granular neutrophil dysfunction may also be present. In order to evaluate infectious burden and immunological function in patients with 11q disorders, we studied a cohort of 14 patients with 11q deletions and duplications. Clinically, 12 patients exhibited prolonged and repetitive respiratory tract infections, frequently requiring (prophylactic) antibiotic treatment (n = 7), ear-tube placement (n = 9), or use of inhalers (n = 5). Complicated varicella infections (n = 5), chronic eczema (n = 6), warts (n = 2), and chronic fungal infections (n = 4) were reported. Six patients were on immunoglobulin replacement therapy. We observed a high prevalence of low B lymphocyte counts (n = 8), decreased T lymphocyte counts (n = 5) and abnormal T lymphocyte function (n = 12). Granulocyte function was abnormal in 29% without a clinical phenotype. Immunodeficiency was found in patients with terminal and interstitial 11q deletions and in one patient with terminal 11q duplication. Genetically, FLI1 and ETS1 are seen as causative for the immunodeficiency, but these genes were deleted nor duplicated in 4 of our 14 patients. Alternative candidate genes on 11q may have a role in immune dysregulation. In conclusion, we present evidence that inborn errors of immunity are present in patients with 11q disorders leading to clinically relevant infections. Therefore, broad immunological screening and necessary treatment is of importance in this patient group. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. International changes in respiratory syncytial virus (RSV) epidemiology during the COVID‐19 pandemic: Association with school closures.
- Author
-
Billard, Marie‐Noëlle, van de Ven, Peter M., Baraldi, Bianca, Kragten‐Tabatabaie, Leyla, Bont, Louis J., and Wildenbeest, Joanne G.
- Subjects
COVID-19 pandemic ,RESPIRATORY syncytial virus ,SCHOOL closings ,PANDEMICS ,EPIDEMIOLOGY ,COVID-19 - Abstract
Background: Little RSV activity was observed during the first expected RSV season since the COVID‐19 pandemic. Multiple countries later experienced out‐of‐season RSV resurgences, yet their association with non‐pharmaceutical interventions (NPIs) is unclear. This study aimed to describe the changes in RSV epidemiology during the COVID‐19 pandemic and to estimate the association between individual NPIs and the RSV resurgences. Methods: RSV activity from Week (W)12‐2020 to W44‐2021 was compared with three pre‐pandemic seasons using RSV surveillance data from Brazil, Canada, Chile, France, Israel, Japan, South Africa, South Korea, Taiwan, the Netherlands and the United States. Changes in nine NPIs within 10 weeks before RSV resurgences were described. Associations between NPIs and RSV activity were assessed with linear mixed models. Adherence to NPIs was not taken into account. Results: Average delay of the first RSV season during the COVID‐19 pandemic was 39 weeks (range: 13–88 weeks). Although the delay was <40 weeks in six countries, a missed RSV season was observed in Brazil, Chile, Japan, Canada and South Korea. School closures, workplace closures, and stay‐at‐home requirements were most commonly downgraded before an RSV resurgence. Reopening schools and lifting stay‐at‐home requirements were associated with increases of 1.31% (p = 0.04) and 2.27% (p = 0.06) in the deviation from expected RSV activity. Conclusion: The first RSV season during the COVID‐19 pandemic was delayed in the 11 countries included. Reopening of schools was consistently associated with increased RSV activity. As NPIs were often changed concomitantly, the association between RSV activity and school closures may be partly attributed to other NPIs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome.
- Author
-
Streng, Bianca M M, Bont, Marin, Delemarre, Eveline M, Binnendijk, Rob S, Smit, Gaby, Hartog, Gerco den, Coppus, Antonia M W, Vries, Esther de, Weijerman, Michel E, Lamberts, Regina, Graaf, Gert de, Klis, Fiona R van der, Vidarsson, Gestur, Rave, Neele, Bont, Louis J, Wildenbeest, Joanne G, den Hartog, Gerco, de Vries, Esther, de Graaf, Gert, and van der Klis, Fiona R
- Abstract
The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age.
Clinical Trials Registration: NCT05145348. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
28. Patient Involvement in RSV Research: Towards Patients Setting the Research Agenda.
- Author
-
Derksen-Lazet, Nicole D, Parmentier, Corline E J, Wildenbeest, Joanne G, Bont, Louis J, Investigators, RESCEU, and RESCEU Investigators
- Subjects
RESPIRATORY syncytial virus ,PATIENT participation ,IMMUNOCOMPROMISED patients ,RESEARCH funding ,RESPIRATORY syncytial virus infections - Abstract
Respiratory syncytial virus (RSV) causes a substantial disease burden among children, elderly and immunocompromised adults. Recognition of patient involvement in research is gradually increasing. Most research is being carried out without active patient involvement other than patients participating as study subjects, and most knowledge gained through research only partially reaches the general public. Since 2016, the RSV Patient Advisory Board has officially been involved as an advisory group in the Respiratory Syncytial Virus Consortium in Europe (RESCEU). What started as a small single-center initiative, is now growing towards an international organization providing patient perspectives as inputs to scientists, and improving awareness of RSV. This article summarizes the history, current role, and future aims of the RSV Patient Advisory Board as an advocate to improve patient involvement in research. RSV patients and their representatives are important stakeholders in setting the global research agenda, and educating patients, professionals, and the general public. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Performance Assessment of a Rapid Molecular Respiratory Syncytial Virus Point-of-Care Test: A Prospective Community Study in Older Adults.
- Author
-
Zuurbier, Roy P, Korsten, Koos, Verheij, Theo J M, Butler, Chris, Adriaenssens, Niels, Coenen, Samuel, Gruselle, Olivier, Vantomme, Valerie, Houten, Marlies A van, Bont, Louis J, Wildenbeest, Joanne G, Investigators, REspiratory Syncytial Virus Consortium in EUrope (RESCEU), van Houten, Marlies A, and REspiratory Syncytial Virus Consortium in EUrope (RESCEU) Investigators
- Subjects
INFLUENZA diagnosis ,RESPIRATORY syncytial virus ,INFLUENZA A virus ,MOLECULAR diagnosis ,NASOPHARYNX ,INFLUENZA B virus ,RESPIRATORY syncytial virus infections ,SENSITIVITY & specificity (Statistics) ,LONGITUDINAL method - Abstract
Background: Respiratory syncytial virus (RSV) causes a substantial burden in older adults. Viral load in RSV-infected adults is generally lower compared to young children, which could result in suboptimal sensitivity of RSV diagnostics. Although the Xpert® Xpress Flu/RSV assay has been used in routine clinical care, its sensitivity to diagnose RSV infection in older adults is largely unknown. We aimed to compare the performance of the Xpert® Xpress Flu/RSV assay with real-time reverse-transcription polymerase chain reaction (RT-PCR) in home-dwelling older adults (≥60 years of age).Methods: Nasopharyngeal swabs were tested with Xpert® Xpress Flu/RSV and compared to RSV RT-PCR in older adults with acute respiratory tract infections with different levels of disease severity.Results: We studied 758 respiratory samples from 561 older adults from 2 consecutive RSV seasons. Thirty-five (4.6%) samples tested positive for RSV by at least 1 of the assays, of which 2 samples were negative by Xpert® Xpress Flu/RSV and 3 samples by real-time RT-PCR. The positive percentage agreement (PPA) was 90.9% (95% confidence interval [CI], 76.4%-96.8%) and negative percentage agreement was 99.7% (95% CI, 99.0%-99.9%). Viral loads were low (≤103 copies/mL or cycle threshold value ≥34) in all cases with discordant results for the 2 assays.Conclusions: The PPA of Xpert® Xpress Flu/RSV compared to routine RT-PCR is high for RSV detection in home-dwelling older adults. The assay is fast and easy to use at the point of care.Clinical Trials Registration: NCT03621930. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
30. Clinical and Viral Factors Associated With Disease Severity and Subsequent Wheezing in Infants With Respiratory Syncytial Virus Infection.
- Author
-
McGinley, Joseph P, Lin, Gu Lung, Öner, Deniz, Golubchik, Tanya, O'Connor, Daniel, Snape, Matthew D, Gruselle, Olivier, Langedijk, Annefleur C, Wildenbeest, Joanne, Openshaw, Peter, Nair, Harish, Aerssens, Jeroen, Bont, Louis, Martinón-Torres, Federico, Drysdale, Simon B, Pollard, Andrew J, Investigators, the RESCEU, and RESCEU Investigators
- Subjects
RESPIRATORY syncytial virus ,SEVERITY of illness index ,RESPIRATORY organ sounds ,HOSPITAL care ,RESEARCH funding ,RESPIRATORY syncytial virus infections ,DISEASE complications - Abstract
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in infants and young children worldwide. Here we evaluated host demographic and viral factors associated with RSV disease severity in 325 RSV-infected infants under 1 year of age from 3 European countries during 2017-2020. Younger infants had a higher clinical severity (ReSViNET) score and were more likely to require hospitalization, intensive care, respiratory support, and/or mechanical ventilation than older infants (<3 months vs 3 to <6 months and 3 to <6 months vs ≥6 months). Older age (≥6 months vs <3 months), higher viral load, and RSV-A were associated with a greater probability of fever. RSV-A and RSV-B caused similar disease severity and had similar viral dynamics. Infants with a more severe RSV infection, demonstrated by having a higher ReSViNET score, fever, and requiring hospitalization and intensive care, were more likely to have developed subsequent wheezing at 1 year of age.
Clinical Trials Registration: NCT03756766. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
31. Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults.
- Author
-
Mao, Zhuxin, Li, Xiao, Korsten, Koos, Bont, Louis, Butler, Christopher, Wildenbeest, Joanne, Coenen, Samuel, Hens, Niel, Bilcke, Joke, Beutels, Philippe, and Investigators, RESCEU
- Abstract
Background Respiratory syncytial virus (RSV) and influenza virus infections result in a considerable mortality and morbidity among the aging population globally. Influenza vaccination for older adults before the seasonal influenza epidemic has been evaluated to be cost-effective in many countries. Interventions against RSV in older adults are in the pipeline, and evaluating their cost-effectiveness is crucial for decision making. To inform such evaluations, our aim was to estimate average costs and health-related quality of life (HRQoL) in older adults with RSV and influenza infection. Methods The European RESCEU observational cohort study followed 1040 relatively healthy community-dwelling older adults aged 60 years and older during 2 consecutive winter seasons. Health care resource use and HRQoL were collected and analyzed during RSV episodes, and also during influenza episodes. Country-specific unit cost data were mainly obtained from national databases. Direct costs were estimated from a patient, health care provider, and health care payers' perspective, whereas indirect costs were estimated from a societal perspective. Due to small sample size, no formal statistical comparisons were made. Results Thirty-six RSV and 60 influenza episodes were reported, including 1 hospitalization. Means (median; first-third quartile) of €26.4 (€5.5; 0–47.3) direct and €4.4 (€0; 0–0) indirect costs were reported per nonhospitalized RSV episode, and €42.5 (€36; 3.3–66.7) direct and €32.1 (€0; 0–0) indirect costs per nonhospitalized influenza episode. For RSV episodes, the utility value decreased from 0.896 (0.928; 0.854–0.953) to 0.801 (0.854; 0.712–0.937) from preseason to 1 week after symptom onset; for influenza, the change was from 0.872 (0.895; 0.828–0.953) to 0.664 (0.686; 0.574–0.797). Conclusions The average costs and HRQoL estimates of older adults treated outside the hospital can be used to inform the design of future studies and the decision making regarding interventions to prevent RSV infection in older adults. Larger studies are needed to provide better country-specific and complementary cost estimates and to allow for formal statistical comparison of costs between RSV and influenza. Clinical Trials Registration NCT03621930. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
- Author
-
Li, Xiao, Bilcke, Joke, Fernández, Liliana Vázquez, Bont, Louis, Willem, Lander, Wisløff, Torbjørn, Jit, Mark, Beutels, Philippe, Investigators, REspiratory Syncytial virus Consortium in EUrope (RESCEU), Vázquez Fernández, Liliana, and REspiratory Syncytial virus Consortium in EUrope (RESCEU) Investigators
- Subjects
THERAPEUTIC use of monoclonal antibodies ,RESPIRATORY syncytial virus ,COMMUNICABLE diseases ,VACCINES ,ANTIVIRAL agents ,COST benefit analysis ,SEASONS ,RESEARCH funding ,RESPIRATORY syncytial virus infections - Abstract
Background: Every winter, respiratory syncytial virus (RSV) disease results in thousands of cases in Norwegian children under 5 years of age. We aim to assess the RSV-related economic burden and the cost-effectiveness of upcoming RSV disease prevention strategies including year-round maternal immunization and year-round and seasonal monoclonal antibody (mAb) programs.Methods: Epidemiological and cost data were obtained from Norwegian national registries, while quality-adjusted life-years (QALYs) lost and intervention characteristics were extracted from literature and phase 3 clinical trials. A static model was used and uncertainty was accounted for probabilistically. Value of information was used to assess decision uncertainty. Extensive scenario analyses were conducted, including accounting for long-term consequences of RSV disease.Results: We estimate an annual average of 13 517 RSV cases and 1572 hospitalizations in children under 5, resulting in 79.6 million Norwegian kroner (~€8 million) treatment costs. At €51 per dose for all programs, a 4-month mAb program for neonates born in November to February is the cost-effective strategy for willingness to pay (WTP) values up to €40 000 per QALY gained. For higher WTP values, the longer 6-month mAb program that immunizes neonates from October to March becomes cost-effective. Sensitivity analyses show that year-round maternal immunization can become a cost-effective strategy if priced lower than mAb.Conclusions: Assuming the same pricing, seasonal mAb programs are cost-effective over year-round programs in Norway. The timing and duration of the cost-effective seasonal program are sensitive to the pattern of the RSV season in a country, so continued RSV surveillance data are essential. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
33. A Systematic Review and Meta-analysis of Animal Studies Investigating the Relationship Between Serum Antibody, T Lymphocytes, and Respiratory Syncytial Virus Disease.
- Author
-
McGinley, Joseph, Thwaites, Ryan, Brebner, Will, Greenan-Barrett, Lewis, Aerssens, Jeroen, Öner, Deniz, Bont, Louis, Wildenbeest, Joanne, Martinón-Torres, Federico, Nair, Harish, Pollard, Andrew J, Openshaw, Peter, Drysdale, Simon, Investigators, REspiratory Syncytial virus Consortium in EUrope (RESCEU), and REspiratory Syncytial virus Consortium in EUrope (RESCEU) Investigators
- Subjects
RESPIRATORY syncytial virus ,RESEARCH ,CATTLE ,META-analysis ,ANIMAL experimentation ,RESEARCH methodology ,SYSTEMATIC reviews ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding ,RESPIRATORY syncytial virus infections ,VIRAL antibodies ,T cells ,MICE - Abstract
Background: Respiratory syncytial virus (RSV) infections occur in human populations around the globe, causing disease of variable severity, disproportionately affecting infants and older adults (>65 years of age). Immune responses can be protective but also contribute to disease. Experimental studies in animals enable detailed investigation of immune responses, provide insights into clinical questions, and accelerate the development of passive and active vaccination. We aimed to review the role of antibody and T-cell responses in relation to RSV disease severity in animals.Methods: Systematic review and meta-analysis of animal studies examining the association between T-cell responses/phenotype or antibody titers and severity of RSV disease. The PubMed, Zoological Record, and Embase databases were screened from January 1980 to May 2018 to identify animal studies of RSV infection that assessed serum antibody titer or T lymphocytes with disease severity as an outcome. Sixty-three studies were included in the final review.Results: RSV-specific antibody appears to protect from disease in mice, but such an effect was less evident in bovine RSV. Strong T-cell, Th1, Th2, Th17, CD4/CD8 responses, and weak Treg responses accompany severe disease in mice.Conclusions: Murine studies suggest that measures of T-lymphocyte activity (particularly CD4 and CD8 T cells) may be predictive biomarkers of severity. Further inquiry is merited to validate these results and assess relevance as biomarkers for human disease. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
34. Contact With Young Children Increases the Risk of Respiratory Infection in Older Adults in Europe-the RESCEU Study.
- Author
-
Korsten, Koos, Adriaenssens, Niels, Coenen, Samuel, Butler, Chris C, Pirçon, Jean Yves, Verheij, Theo J M, Bont, Louis J, Wildenbeest, Joanne G, Investigators, RESCEU, and RESCEU Investigators
- Subjects
RESPIRATORY infections ,RESEARCH funding ,ODDS ratio - Abstract
Background: Knowledge about how older adults get a respiratory infection is crucial for planning preventive strategies. We aimed to determine how contact with young children living outside of the household affects the risk of acute respiratory tract infections (ARTI) in community-dwelling older adults.Methods: This study is part of the European RESCEU older adult study. Weekly surveillance was performed to detect ARTI throughout 2 winter seasons (2017-2018, 2018-2019). Child exposure, defined as having regular contact with children under 5 living outside of the subject's household, was assessed at baseline. The average attributable fraction was calculated to determine the fraction of ARTI explained by exposure to these children.Results: We prospectively established that 597/1006 (59%) participants experienced at least 1 ARTI. Child exposure increased the risk of all-cause ARTI (adjusted odds ratio [aOR], 1.58; 95% confidence interval [CI], 1.21 -2.08; P = .001). This risk was highest in those with the most frequent contact (aOR, 1.80; 95% CI, 1.23-2.63; P = .003). The average attributable fraction of child exposure explaining ARTI was 10% (95% CI, 5%-15%).Conclusions: One of 10 ARTI in community-dwelling older adults is attributable to exposure to preschool children living outside of the household.Clinical Trials Registration: NCT03621930. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
35. World Health Organization Influenza-Like Illness Underestimates the Burden of Respiratory Syncytial Virus Infection in Community-Dwelling Older Adults.
- Author
-
Korsten, Koos, Adriaenssens, Niels, Coenen, Samuel, Butler, Chris C, Verheij, Theo J M, Bont, Louis J, Wildenbeest, Joanne G, Investigators, RESCEU, and RESCEU Investigators
- Subjects
INFLUENZA diagnosis ,INFLUENZA epidemiology ,RESPIRATORY syncytial virus ,FEVER ,RESPIRATORY infections ,VIRUS diseases ,INDEPENDENT living ,IMPACT of Event Scale ,QUESTIONNAIRES ,RESEARCH funding ,RESPIRATORY syncytial virus infections ,LONGITUDINAL method - Abstract
Background: Respiratory syncytial virus (RSV) surveillance is heavily dependent on the influenza-like illness (ILI) case definition from the World Health Organization (WHO). Because ILI includes fever in its syndromic case definition, its ability to accurately identify acute respiratory tract infections (ARTI) caused by RSV in older adults is uncertain.Methods: The accuracy of the WHO ILI and a modified ILI (requiring only self-reported fever) case definitions in identifying patients with PCR-confirmed RSV-ARTI was evaluated in community-dwelling older adults (≥60 years) from the prospective European RESCEU cohort study.Results: Among 1040 participants, 750 ARTI episodes were analyzed including 36 confirmed RSV-ARTI. Due to a general lack of fever, sensitivity for RSV-ARTI was 33% for modified ILI and 11% for ILI. The area under the curve for both ILI definitions was 0.52 indicating poor discrimination for RSV. RSV-ARTI could not be distinguished from all other ARTI based on clinical symptoms.Conclusions: The use of ILI underestimated the occurrence of RSV-ARTI in community-dwelling older adults up to 9-fold (11% sensitivity). Because worldwide RSV surveillance depends largely on ILI, there is an urgent need for a better approach to measure the occurrence of RSV disease and the impact of future RSV vaccine introduction. Clinical Trials Registration. NCT03621930. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
36. SOCIAL LISTENING AND GOOGLE TRENDS AS TOOLS FOR ESTIMATING PUBLIC AWARENESS OF RESPIRATORY SYNCYTIAL VIRUS.
- Author
-
Schuurman, Gillian Samantha and Bont, Louis
- Published
- 2022
- Full Text
- View/download PDF
37. DISAGREEMENT FDA AND EMA ON RSV MATERNAL VACCINATION: Possible Consequence for Global Mortality.
- Author
-
Willemsen, Joukje E., Borghans, José A. M., Bont, Louis J., and Drylewicz, Julia
- Published
- 2024
- Full Text
- View/download PDF
38. A systematic review on global RSV genetic data: Identification of knowledge gaps.
- Author
-
Langedijk, Annefleur C., Harding, Eline R., Konya, Burak, Vrancken, Bram, Lebbink, Robert Jan, Evers, Anouk, Willemsen, Joukje, Lemey, Philippe, and Bont, Louis J.
- Abstract
Respiratory syncytial virus (RSV) is a major health problem. A better understanding of the geographical and temporal dynamics of RSV circulation will assist in tracking resistance against therapeutics currently under development. Since 2015, the field of RSV molecular epidemiology has evolved rapidly with around 20–30 published articles per year. The objective of this systematic review is to identify knowledge gaps in recent RSV genetic literature to guide global molecular epidemiology research. We included 78 studies published between 2015 and 2020 describing 12,998 RSV sequences of which 8,233 (63%) have been uploaded to GenBank. Seventeen (22%) studies were performed in low‐ and middle‐income countries (LMICs), and seven (9%) studies sequenced whole‐genomes. Although most reported polymorphisms for monoclonal antibodies in clinical development (nirsevimab, MK‐1654) have not been tested for resistance in neutralisation essays, known resistance was detected at low levels for the nirsevimab and palivizumab binding site. High resistance was found for the suptavumab binding site. We present the first literature review of an enormous amount of RSV genetic data. The need for global monitoring of RSV molecular epidemiology becomes increasingly important in evaluating the effectiveness of monoclonal antibody candidates as they reach their final stages of clinical development. We have identified the following three knowledge gaps: whole‐genome data to study global RSV evolution, data from LMICs and data from global surveillance programs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. Rotavirus Vaccine Safety and Effectiveness in Infants With High-Risk Medical Conditions.
- Author
-
van Dongen, Josephine A. P., Rouers, Elsbeth D. M., Schuurman, Rob, Band, Caterina, Watkins, Shannon M., van Houten, Marlies A., Bont, Louis J., Norbruis, Obbe F., Hemels, Marieke A. C., van Well, Gijs T. J., Vlieger, Arine M., van der Sluijs, Jacqueline, Stas, Helene G., Tramper-Stranders, Gerdien, Kleinlugtenbeld, Elly A., van Kempen, Anne A. M. W., Wessels, Margreet, van Rossem, Maaike C., Dassel, Carin A. C. M., and Pajkrt, Dasja
- Published
- 2021
- Full Text
- View/download PDF
40. Impact of COVID‐19 social distancing on viral infection in France: A delayed outbreak of RSV.
- Author
-
Delestrain, Céline, Danis, Kostas, Hau, Isabelle, Behillil, Sylvie, Billard, Marie‐Noëlle, Krajten, Leyla, Cohen, Robert, Bont, Louis, and Epaud, Ralph
- Published
- 2021
- Full Text
- View/download PDF
41. Infant RSV immunoprophylaxis changes nasal epithelial DNA methylation at 6 years of age.
- Author
-
Xu, Cheng‐Jian, Scheltema, Nienke M., Qi, Cancan, Vedder, Rolf, Klein, Laura B. C., Nibbelke, Elisabeth E., van der Ent, Cornelis K., Bont, Louis J., and Koppelman, Gerard H.
- Published
- 2021
- Full Text
- View/download PDF
42. COVID-19 Lesson for Respiratory Syncytial Virus (RSV): Hygiene Works.
- Author
-
Gastaldi, Andrea, Donà, Daniele, Barbieri, Elisa, Giaquinto, Carlo, Bont, Louis J., and Baraldi, Eugenio
- Subjects
COVID-19 pandemic ,RESPIRATORY syncytial virus ,HYGIENE ,RESPIRATORY infections ,CHILDREN'S health - Abstract
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (LRTIs) in infants worldwide. The global direct medical cost associated with RSV LRTIs reaches billions of dollars, with the highest burden in low–middle-income countries. Many efforts have been devoted to improving its prevention and management, including both non-pharmaceutical and pharmaceutical strategies, often with limited routine use in high-income countries due to high costs. During the ongoing COVID-19 pandemic, a dramatic decrease in RSV infections (up to 70–90%) has been reported around the globe, directly related to the implementation of containment measures (face masks, hand hygiene, and social distancing). Primary prevention has demonstrated the highest cost effectiveness ratio in reducing the burden of a respiratory infection such as RSV, never reached before. Thus, we emphasize the importance of non-pharmaceutical preventive hygiene measures that should be implemented and maintained even after the COVID-19 outbreak. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
43. RSV: perspectives to strengthen the need for protection in all infants.
- Author
-
Navarro Alonso, Jose Antonio, Bont, Louis J., Bozzola, Elena, Herting, Egbert, Lega, Federico, Mader, Silke, Nunes, Marta C., Ramilo, Octavio, Valiotis, George, Olivier, Catherine Weil, Yates, Ann, and Faust, Saul N.
- Subjects
RESPIRATORY syncytial virus ,GLOBAL burden of disease ,RESPIRATORY syncytial virus infections ,INFANT mortality ,DISEASE complications - Abstract
Respiratory syncytial virus (RSV)—the most common viral cause of bronchiolitis—is a significant cause of serious illness among young children between the ages of 0–5 years and is especially concerning in the first year of life. Globally, RSV is a common cause of childhood acute lower respiratory illness (ALRI) and a major cause of hospital admissions in young children and infants and represents a substantial burden for health-care systems. This burden is strongly felt as there are currently no effective preventative options that are available for all infants. However, a renaissance in RSV prevention strategies is unfolding, with several new prophylactic options such as monoclonal antibodies and maternal vaccinations that are soon to be available. A key concern is that health decision makers and systems may not be ready to take full advantage of forthcoming technological innovations. A multi-stakeholder approach is necessary to bridge data gaps to fully utilise upcoming options. Knowledge must be made available at multiple levels to ensure that parents and doctors are aware of preventative options, but also to ensure that stakeholders and policymakers are given the necessary information to best advise implementation strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
44. Burden of respiratory syncytial virus bronchiolitis on the Dutch pediatric intensive care units.
- Author
-
Linssen, Rosalie S., Bem, Reinout A., Kapitein, Berber, Rengerink, Katrien Oude, Otten, Marieke H., den Hollander, Bibiche, Bont, Louis, van Woensel, Job B. M., on behalf of the PICE Study Group, Wösten-van Asperen, Roelie M., Klein, Richard H., Kneyber, Martin C. J., Kuiper, Jan Willem, Verlaat, Carin, van Heerde, Marc, Riedijk, Maaike A., and van Waardenburg, Dick A.
- Subjects
BRONCHIOLITIS ,PEDIATRIC intensive care ,INTENSIVE care units ,RESPIRATORY syncytial virus ,PEDIATRIC therapy ,NASAL cannula - Abstract
Respiratory syncytial virus (RSV) bronchiolitis causes substantial morbidity and mortality in young children, but insight into the burden of RSV bronchiolitis on pediatric intensive care units (PICUs) is limited. We aimed to determine the burden of RSV bronchiolitis on the PICUs in the Netherlands. Therefore, we identified all children ≤ 24 months of age with RSV bronchiolitis between 2003 and 2016 from a nationwide PICU registry. Subsequently we manually checked their patient records for correct diagnosis and collected patient characteristics, additional clinical data, respiratory support modes, and outcome. In total, 2161 children were admitted to the PICU for RSV bronchiolitis. The annual number of admissions increased significantly during the study period (β 4.05, SE 1.27, p = 0.01), and this increase was mostly driven by increased admissions in children up to 3 months old. Concomitantly, non-invasive respiratory support significantly increased (β 7.71, SE 0.92, p < 0.01), in particular the use of high flow nasal cannula (HFNC) (β 6.69, SE 0.96, p < 0.01), whereas the use of invasive ventilation remained stable. Conclusion: The burden of severe RSV bronchiolitis on PICUs has increased in the Netherlands. Concomitantly, the use of non-invasive respiratory support, especially HFNC, has increased. What is Known: • RSV bronchiolitis is a major cause of childhood morbidity and mortality and may require pediatric intensive care unit admission. • The field of pediatric critical care for severe bronchiolitis has changed due to increased non-invasive respiratory support options. What is New: • The burden of RSV bronchiolitis for the Dutch PICUs has increased. These data inform future strategic PICU resource planning and implementation of RSV preventive strategies. • There was a significant increase in the use of high flow nasal cannula at the PICU, but the use of invasive mechanical ventilation did not decrease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
45. Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics: the RSV GOLD-III study protocol.
- Author
-
Löwensteyn, Yvette N., Mazur, Natalie I., Nair, Harish, Willemsen, Joukje E., van Thiel, Ghislaine, Bont, Louis, the RSV GOLD III—ICU Network study group, Garba, Maria Ahuoiza, Giwa, Fatima Jumai, Rasooly, Mohammad Hafiz, Shirpoor, Aminullah, Azizyar, Merwais, Makalo, Lamin, Nyan, Ousman, Mohamed, Ali, Osman, Khalid, Chapagain, Ram Hari, Bista, Krishna Prasad, Sharma, Arun Kumar, and Shrestha, Prabina
- Subjects
INTENSIVE care units ,POINT-of-care testing ,RESEARCH protocols ,MOLECULAR diagnosis ,PEDIATRIC intensive care ,BRONCHIOLITIS ,HUMAN metapneumovirus infection - Abstract
Background: Respiratory syncytial virus (RSV) infection is an important cause of hospitalization and death in young children. The majority of deaths (99%) occur in low- and lower-middle-income countries (LMICs). Vaccines against RSV infection are underway. To obtain access to RSV interventions, LMICs depend on support from Gavi, the Vaccine Alliance. To identify future vaccine target populations, information on children with severe RSV infection is required. However, there is a lack of individual patient-level clinical data on instances of life-threatening RSV infection in LMICs. The RSV GOLD III—ICU Network study aims to describe clinical, demographic and socioeconomic characteristics of children with life-threatening RSV infection in Gavi-eligible countries. Methods: The RSV GOLD-III—ICU Network study is an international, prospective, observational multicenter study and will be conducted in 10 Gavi-eligible countries at pediatric intensive care units and high-dependency units (PICUs/HDUs) during local viral respiratory seasons for 2 years. Children younger than 2 years of age with respiratory symptoms fulfilling the World Health Organization (WHO) "extended severe acute respiratory infection (SARI)" case definition will be tested for RSV using a molecular point-of-care (POC) diagnostic device. Patient characteristics will be collected through a questionnaire. Mortality rates of children admitted to the PICU and/or HDU will be calculated. Discussion: This multicenter descriptive study will provide a better understanding of the characteristics and mortality rates of children younger than 2 years with RSV infection admitted to the PICU/HDU in LMICs. These results will contribute to knowledge on global disease burden and awareness of RSV and will directly guide decision makers in their efforts to implement future RSV prevention strategies. Trial registration number: NL9519, May 27, 2021 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus.
- Author
-
Lin, Gu-Lung, Drysdale, Simon B., Snape, Matthew D., O'Connor, Daniel, Brown, Anthony, MacIntyre-Cockett, George, Mellado-Gomez, Esther, de Cesare, Mariateresa, Bonsall, David, Ansari, M. Azim, Öner, Deniz, Aerssens, Jeroen, Butler, Christopher, Bont, Louis, Openshaw, Peter, Martinón-Torres, Federico, Nair, Harish, Bowden, Rory, RESCEU Investigators, and Campbell, Harry
- Subjects
RESPIRATORY syncytial virus ,AMINO acid sequence ,VACCINE effectiveness ,MONOCLONAL antibodies ,PALIVIZUMAB ,VACCINE development ,RESPIRATORY infections - Abstract
Human respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in young children globally, but little is known about within-host RSV diversity. Here, we characterised within-host RSV populations using deep-sequencing data from 319 nasopharyngeal swabs collected during 2017–2020. RSV-B had lower consensus diversity than RSV-A at the population level, while exhibiting greater within-host diversity. Two RSV-B consensus sequences had an amino acid alteration (K68N) in the fusion (F) protein, which has been associated with reduced susceptibility to nirsevimab (MEDI8897), a novel RSV monoclonal antibody under development. In addition, several minor variants were identified in the antigenic sites of the F protein, one of which may confer resistance to palivizumab, the only licensed RSV monoclonal antibody. The differences in within-host virus populations emphasise the importance of monitoring for vaccine efficacy and may help to explain the different prevalences of monoclonal antibody-escape mutants between the two subgroups. Respiratory syncytial virus (RSV) is a common infection in children and older adults but little is known about within-host viral population diversity. Here, the authors perform deep sequencing and find that RSV subgroup B exhibited more diversity than subgroup A, with implications for development of therapeutics and vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. Describing global pediatric RSV disease at intensive care units in GAVI-eligible countries using molecular point-of-care diagnostics: the RSV GOLD-III study protocol.
- Author
-
Löwensteyn, Yvette N., Mazur, Natalie I., Nair, Harish, Willemsen, Joukje E., van Thiel, Ghislaine, Bont, Louis, the RSV GOLD III—ICU Network study group, Garba, Maria Ahuoiza, Giwa, Fatima Jumai, Rasooly, Mohammad Hafiz, Shirpoor, Aminullah, Azizyar, Merwais, Makalo, Lamin, Nyan, Ousman, Mohamed, Ali, Osman, Khalid, Chapagain, Ram Hari, Bista, Krishna Prasad, Sharma, Arun Kumar, and Shrestha, Prabina
- Subjects
INTENSIVE care units ,POINT-of-care testing ,RESEARCH protocols ,PEDIATRIC intensive care ,MOLECULAR diagnosis ,BRONCHIOLITIS ,HUMAN metapneumovirus infection ,RESPIRATORY syncytial virus ,RESEARCH ,MEDICAL databases ,INFORMATION storage & retrieval systems ,MEDICAL cooperation ,PEDIATRICS ,CLINICAL medicine ,HOSPITAL care ,RESEARCH funding ,RESPIRATORY syncytial virus infections ,LONGITUDINAL method - Abstract
Background: Respiratory syncytial virus (RSV) infection is an important cause of hospitalization and death in young children. The majority of deaths (99%) occur in low- and lower-middle-income countries (LMICs). Vaccines against RSV infection are underway. To obtain access to RSV interventions, LMICs depend on support from Gavi, the Vaccine Alliance. To identify future vaccine target populations, information on children with severe RSV infection is required. However, there is a lack of individual patient-level clinical data on instances of life-threatening RSV infection in LMICs. The RSV GOLD III-ICU Network study aims to describe clinical, demographic and socioeconomic characteristics of children with life-threatening RSV infection in Gavi-eligible countries.Methods: The RSV GOLD-III-ICU Network study is an international, prospective, observational multicenter study and will be conducted in 10 Gavi-eligible countries at pediatric intensive care units and high-dependency units (PICUs/HDUs) during local viral respiratory seasons for 2 years. Children younger than 2 years of age with respiratory symptoms fulfilling the World Health Organization (WHO) "extended severe acute respiratory infection (SARI)" case definition will be tested for RSV using a molecular point-of-care (POC) diagnostic device. Patient characteristics will be collected through a questionnaire. Mortality rates of children admitted to the PICU and/or HDU will be calculated.Discussion: This multicenter descriptive study will provide a better understanding of the characteristics and mortality rates of children younger than 2 years with RSV infection admitted to the PICU/HDU in LMICs. These results will contribute to knowledge on global disease burden and awareness of RSV and will directly guide decision makers in their efforts to implement future RSV prevention strategies.Trial Registration Number: NL9519, May 27, 2021. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
48. Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level.
- Author
-
Salimi, Vahid, Viegas, Mariana, Trento, Alfonsina, Agoti, Charles N., Anderson, Larry J., Avadhanula, Vasanthi, Bahl, Justin, Bont, Louis, Brister, J. Rodney, Cane, Patricia A., Galiano, Mónica, Graham, Barney S., Hatcher, Eneida L., Hellferscee, Orienka, Henke, David M., Hirve, Siddhivinayak, Jackson, Sandra, Keyaerts, Els, Kragten-Tabatabaie, Leyla, and Lindstrom, Stephen
- Subjects
RESPIRATORY syncytial virus ,RESEARCH ,BIOLOGICAL evolution ,GENETICS ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,GENOTYPES ,RESPIRATORY syncytial virus infections ,MOLECULAR epidemiology - Abstract
Human respiratory syncytial virus (HRSV) is the leading viral cause of serious pediatric respiratory disease, and lifelong reinfections are common. Its 2 major subgroups, A and B, exhibit some antigenic variability, enabling HRSV to circulate annually. Globally, research has increased the number of HRSV genomic sequences available. To ensure accurate molecular epidemiology analyses, we propose a uniform nomenclature for HRSV-positive samples and isolates, and HRSV sequences, namely: HRSV/subgroup identifier/geographic identifier/unique sequence identifier/year of sampling. We also propose a template for submitting associated metadata. Universal nomenclature would help researchers retrieve and analyze sequence data to better understand the evolution of this virus. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. Are We Ready for Maternal Respiratory Syncytial Virus Vaccination?
- Author
-
Phijffer, Emily W E M and Bont, Louis J
- Abstract
Keywords: maternal vaccination; RSV; vaccines EN maternal vaccination RSV vaccines 2053 2055 3 06/17/22 20220615 NES 220615 B (See the Major Article by Falsey et al on pages 2056-66.) The World Health Organization Product Development for Vaccines Advisory Committee identified the development of maternal RSV vaccines as a priority [[3]], and investigators have become increasingly interested in development of maternal RSV vaccines in recent years. Depending on vaccine efficacy, a maternal RSV vaccine may prevent 29%-48% of RSV-related in-hospital deaths globally [[2]]. RSV pre-F vaccines (with or without concomitant influenza vaccine) showed similar and robust RSV serum neutralizing 1 month postvaccination, in line with data by Peterson et al [[16]]. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
50. TIPICO X: report of the 10th interactive infectious disease workshop on infectious diseases and vaccines.
- Author
-
Rivero-Calle, Irene, Gómez-Rial, Jose, Bont, Louis, Gessner, Bradford D., Kohn, Melvin, Dagan, Ron, Payne, Daniel C., Bruni, Laia, Pollard, Andrew J., García-Sastre, Adolfo, Faustman, Denise L., Osterhaus, Albert, Butler, Robb, Sánchez, Francisco Giménez, Álvarez, Francisco, Kaforou, Myrsini, Bello, Xabier, and Martinón-Torres, Federico
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.